Gyros Protein Technologies introduces Gyrolab xPand to improve immunoassay workflow, flexibility and speed in biotherapeutic discovery, development and production

Mar 22, 2018

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassay platforms and leading provider of peptide synthesizers and reagents, today introduced a new 5 CD model, Gyrolab® xPand, in response to customer requests to provide higher throughput, greater flexibility and faster analysis of large sample numbers. Gyrolab technology significantly accelerates the process of discovering and developing new and safer biotherapeutics. The introduction of Gyrolab xPand reflects the on-going evolution of the Gyrolab platform, with ever more advanced instrumentation and software designed for 21 CFR part 11 compliance. During assay runs, the new multi-CD platform maintains samples at 2 – 8°C, ...

Read More

Accurate Protein Electrostatics Add a New Dimension to Structure-based Drug Design

Jan 4, 2018

The combination of advanced molecular force fields and improved visualisation capabilities has enabled chemists to expand their ligand-only view of the electrostatics of their system to include proteins, water and ligands. Important insights into the causes of ligand binding are now available on desktop computers and laptops, giving chemists unprecedented control over drug design. Dr Tim Cheeseright and Katriona Scoffin of Cresset look into electrostatic interactions, at the heart of drug discovery. ...

Read More

ProImmune introduces MutaMap high-throughput service for mutational activity maps of therapeutic proteins

Dec 12, 2017

ProImmune, a leader in services for understanding immune responses, has announced the introduction of MutaMap™, a new high-throughput assay service for understanding the impact of point mutations on protein therapeutic activity, including monoclonal antibodies. MutaMap provides a high-throughput service, with high-quality output data, to help decide which individual point mutations to pursue and enable better protein engineering decisions to be made, prior to committing a drug candidate to a clinical program. MutaMap is an in vitro assay system that explores the effect of deliberate point mutations on protein activity by substituting each of the 19 possible amino acid alternatives in ...

Read More